Novonesis (Novozymes) B (FRA:NZM2)
€ 54.8 -0.20 (-0.36%) Market Cap: 25.64 Bil Enterprise Value: 28.53 Bil PE Ratio: 43.02 PB Ratio: 2.35 GF Score: 95/100

Half Year 2025 Novozymes A/S Earnings Call Transcript

Aug 21, 2025 / 07:00AM GMT
Release Date Price: €52.48 (-5.75%)
Operator

Good morning, ladies and gentlemen, and welcome to the Novonesis Conference Call regarding the first half 2025 financial results as well as the 2030 growth strategy. My name is Josef, the Chorus Call operator. (Operator Instructions) This conference will be recorded. (Operator Instructions) This conference must not be recorded for publication or for broadcast.

At this time, it's my pleasure to hand over to Tobias Cornelius Bjorklund. Please go ahead.

Tobias Bjorklund;S;Head of Investor Relations
Novonesis A

/-

Thank you, operator, and welcome, everyone, to the Novonesis conference call, both for the first half of '25 and also including the presentation of the 2030 strategy and financial targets.

In this call, our CEO, Ester Baiget; and our CFO, Rainer Lehmann, will review our performance for the first half of the year as well as the outlook for 2025. Attending today's call, we have the full executive leadership team, Henrik Joerck Nielsen, EVP of Human Health Biosolutions; Andrew Taylor, EVP of Food &

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot